Skip to main content
  • Home
  • CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use

CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use

Topic:
  • Prevention

Available Credit:

  • 2 EBAC

Course Published On:

Course Expiry Date:

This content is not intended for UK or US HCPs

Overview

The purpose of this programme, 'CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use', is to equip cardiologists with the most up-to-date clinical data to facilitate the adoption of GLP-1 RAs. The programme will provide comprehensive education on the current issues related to CVD and GLP-1 RA treatment, ensuring appropriate implementation of guideline recommendations and creating a shift towards the optimal use of these agents as part of routine CV care.

 

Prof Tina Vilsbøll (Steno Diabetes Centre, Copenhagen, DK) leads proceedings, and is joined by Dr John Buse (University of North Carolina, School of Medicine, Chapel Hill, US), Dr Neha Pagidipati (Duke Clinical Research Institute, Durham, US), and Dr Linda G Mellbin (Karolinska Institute, Stockholm, SE) for insightful presentations and engaging discussions.

Support Statement

This programme is created by Radcliffe Medical Education and Supported by an unrestricted educational grant by Novo Nordisk A/S.

Disclosure

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. This programme is created by Radcliffe Medical Education and Supported by an unrestricted educational grant by Novo Nordisk A/S.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

The session, 'CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use' is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 2 hours of external CME credits. 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Instruction to Participants

There is no fee for taking part in this online learning activity.

Activities are designed to be completed within 120 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

This programme is intended to educate:

  • Cardiologists
  • Endocrinologist/diabetologists
  • Nephrologists
  • GPs

Learning Objectives

The overall programme, "CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use", endeavours to best address the following learning objectives:

  • Describe the burden of ASCVD in type 2 diabetes
  • Assign risk of future CV events to individuals with type 2 diabetes
  • Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
  • Recall trial data of anti-diabetes medications that reduce ASCVD risk
  • Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
  • Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
  • Adopt anti-diabetic therapies with proven ASCVD benefit
Register now Log in

Module

Title

Duration

Speakers

MACE IN T2D: WHICH PATIENTS ARE HIGH RISK? Optimal Approach To Establishing Risk 7m 36s Linda Mellbin
MACE IN T2D: WHICH PATIENTS ARE HIGH RISK? The Complex Relationship Between ASCVD & T2D 6m 34s Tina Vilsbøll
MACE IN T2D: WHICH PATIENTS ARE HIGH RISK? CVD Risk Classification: How Can It Be Better? CV Perspective 4m 3s Linda Mellbin
MACE IN T2D: WHICH PATIENTS ARE HIGH RISK? CVD Risk Classification: How Can It Be Better? Endo perspective 3m 54s Tina Vilsbøll
ADDRESSING HIGH CVD RISK: A PATIENT-TAILORED APPROACH Antihyperglycemics: The Key Players in CV Outcomes 10m 52s John Buse
ADDRESSING HIGH CVD RISK: A PATIENT-TAILORED APPROACH A Deep Dive Into HF & Renal Outcomes 5m 23s Linda Mellbin
ADDRESSING HIGH CVD RISK: A PATIENT-TAILORED APPROACH A Deep Dive Into ASCVD Outcomes 5m 59s Linda Mellbin
OPTIMISING THERAPY IN HIGH-RISK PATIENTS T2D: Tackling Early & Hard 10m 28s Tina Vilsbøll
OPTIMISING THERAPY IN HIGH-RISK PATIENTS QOL: A Holistic View of GLP-1 RAs 9m 38s Neha J Pagidipati
PRACTICAL USE OF GLP-1 RAS: AN EVERYDAY GUIDE Guidance For GLP-1 RAs in CAD: How The Approach Is Changing 13m 17s John Buse
PRACTICAL USE OF GLP-1 RAS: AN EVERYDAY GUIDE GLP-1 RAs: Implementation in Real World Practice 10m 48s Neha J Pagidipati
MULTIDISCIPLINARY CARE OF HIGH-RISK T2D: HOW EVERYONE CAN PLAY A PART Identifying High-risk: How To Stop Patients Slipping Through the Net 11m 9s Tina Vilsbøll Neha J Pagidipati John Buse Linda Mellbin
MULTIDISCIPLINARY CARE OF HIGH-RISK T2D: HOW EVERYONE CAN PLAY A PART GLP-1 RA Therapy: Getting Started & Staying on Track 12m 49s Tina Vilsbøll Neha J Pagidipati John Buse Linda Mellbin
MULTIDISCIPLINARY CARE OF HIGH-RISK T2D: HOW EVERYONE CAN PLAY A PART The MDT: Assembling the Best Care 10m 40s Tina Vilsbøll Neha J Pagidipati John Buse Linda Mellbin
MACE IN T2D: WHICH PATIENTS ARE HIGH RISK?.

Optimal Approach To Establishing Risk

Duration: 7m 36s

Speakers: Linda Mellbin

MACE IN T2D: WHICH PATIENTS ARE HIGH RISK?.

The Complex Relationship Between ASCVD & T2D

Duration: 6m 34s

Speakers: Tina Vilsbøll

MACE IN T2D: WHICH PATIENTS ARE HIGH RISK?.

CVD Risk Classification: How Can It Be Better? CV Perspective

Duration: 4m 3s

Speakers: Linda Mellbin

MACE IN T2D: WHICH PATIENTS ARE HIGH RISK?.

CVD Risk Classification: How Can It Be Better? Endo perspective

Duration: 3m 54s

Speakers: Tina Vilsbøll

ADDRESSING HIGH CVD RISK: A PATIENT-TAILORED APPROACH.

Antihyperglycemics: The Key Players in CV Outcomes

Duration: 10m 52s

Speakers: John Buse

ADDRESSING HIGH CVD RISK: A PATIENT-TAILORED APPROACH.

A Deep Dive Into HF & Renal Outcomes

Duration: 5m 23s

Speakers: Linda Mellbin

ADDRESSING HIGH CVD RISK: A PATIENT-TAILORED APPROACH.

A Deep Dive Into ASCVD Outcomes

Duration: 5m 59s

Speakers: Linda Mellbin

OPTIMISING THERAPY IN HIGH-RISK PATIENTS.

T2D: Tackling Early & Hard

Duration: 10m 28s

Speakers: Tina Vilsbøll

OPTIMISING THERAPY IN HIGH-RISK PATIENTS.

QOL: A Holistic View of GLP-1 RAs

Duration: 9m 38s

Speakers: Neha J Pagidipati

PRACTICAL USE OF GLP-1 RAS: AN EVERYDAY GUIDE.

Guidance For GLP-1 RAs in CAD: How The Approach Is Changing

Duration: 13m 17s

Speakers: John Buse

PRACTICAL USE OF GLP-1 RAS: AN EVERYDAY GUIDE.

GLP-1 RAs: Implementation in Real World Practice

Duration: 10m 48s

Speakers: Neha J Pagidipati

MULTIDISCIPLINARY CARE OF HIGH-RISK T2D: HOW EVERYONE CAN PLAY A PART.

Identifying High-risk: How To Stop Patients Slipping Through the Net

Duration: 11m 9s

Speakers: Tina Vilsbøll Neha J Pagidipati John Buse Linda Mellbin

MULTIDISCIPLINARY CARE OF HIGH-RISK T2D: HOW EVERYONE CAN PLAY A PART.

GLP-1 RA Therapy: Getting Started & Staying on Track

Duration: 12m 49s

Speakers: Tina Vilsbøll Neha J Pagidipati John Buse Linda Mellbin

MULTIDISCIPLINARY CARE OF HIGH-RISK T2D: HOW EVERYONE CAN PLAY A PART.

The MDT: Assembling the Best Care

Duration: 10m 40s

Speakers: Tina Vilsbøll Neha J Pagidipati John Buse Linda Mellbin

Chair

Tina Vilsbøll

Head of Clinic at Steno Diabetes Center, Copenhagen, Denmark

Prof Tina Vilsbøll is a Clinical Professor and Head of Clinic at Steno Diabetes Center, Copenhagen, Denmark.

View full profile
Neha J Pagidipati

Neha J Pagidipati

Duke Clinical Research Institute, Durham, US

Dr Neha J Pagidipati is an Assistant Professor of Medicine and cardiovascular disease prevention specialist. Since 2011, she has conducted research on cardiometabolic disease prevention, lifestyle modification and weight management.

View full profile

Speaker

John Buse

University of North Carolina, School of Medicine, Chapel Hill, US

Dr Buse’s practice combines clinical care, research and education. He has received international recognition for innovative clinical care and efforts at prevention of type 1 diabetes, type 2 diabetes and their complications.

View full profile

Linda Mellbin

Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, SE

Dr Linda Mellbin is Associate Professor of Cardiology and Head of the Coronary Artery Disease Patient Area at Karolinska University Hospital in Stockholm, Sweden.

View full profile

2.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Related Courses

Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more
Imaging vs Angiography-led PCI: An Overview for DES Implantation
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Imaging vs angiography-led PCI: What does success look like?
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Imaging-based Procedure-planning with OCT: Application to Clinical Practice
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
ADVANCES IN IMAGING: OPTIMISING MR AND CT IN DAILY PRACTICE
  • 2.00 EBAC

Learning objectives

  • Interpret existing clinical and meta data for use of pre-procedural, image-aided ablation in ventricular arrhythmias
  • Identify where pre-procedural imaging may complement the current ablation workflow in ventricular arrhythmias
  • Recall the clinical benefits of quantitative, MRI-based approaches to evaluate ischaemia
  • Apply quantitative CMR imaging to complement existing procedural workflows in revascularisation procedures
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Dual antiplatelet therapy for acute stroke and TIA
  • 1.00 EBAC

Learning objectives

  • To highlight the continued high unmet need for strategies to prevent stroke or death for patients experiencing acute stroke or TIA
  • To outline the guidelines on the use of dual antiplatelet therapy for patients presenting with acute stroke or TIA
  • To examine recent evidence from clinical trials on novel strategies for improving outcomes for patients presenting with acute stroke or TIA and how these data and insights can be applied in clinical practice
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more